ClinicalTrials.gg
Not yet recruitingNCT07850999Updated Oct 16, 2026

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function

A Phase 1 interventional study of ABI-6250 in Mild Hepatic Imparement, sponsored by Assembly Biosciences. Not yet recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Assembly Biosciences · Phase 1, Interventional, and Treatment

Updated Oct 16, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.

02

Conditions studied

  • Mild Hepatic Imparement
03

In context

Lead sponsor

Assembly Biosciences is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to provide written , is available for the entire study period, is able to understand and comply with study requirements, procedures and restrictions, able to remain at the clinical research unit (CRU) for the required study duration and return to the CRU for outpatient assessments.
  • Participant has a (BMI) of 18.0 to 45.0 kg/m2, is a non/ex/light-smoker, and is willing and able to swallow whole tablets without breaking, butting or chewing.
  • Renal function, as measured by calculated using the 2009 CKD-EPI equation >60 mL/min at Screening.
  • Female participants must be nonpregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -2.
  • Participants must agree to comply with protocol-specified requirements.
  • Suitable venous access for blood sample collection.

Inclusion Criteria for Participants with Mild Hepatic Impairment (Cohort 1):

  • Stable mild hepatic impairment designated as Class A score of 5 to 6 during Screening and Day -2.
  • Must meet certain laboratory parameters as Screening.
  • Has medical history, clinical lab test results, vital sign measurements and physical examination consistent with stable mild hepatic impairment, as determined by the Investigator.
  • On stable medication regiment for at least 14 days before dosing on Day 1.

Inclusion Criteria for Participants with Normal Hepatic Function (Cohort 2):

  • Has stable normal hepatic function as determined at Screening and Day -2.
  • Medically healthy, as determined by no finding from medical history, clinical lab test results, vital sign measurements, 12-lead results, and physical examination results.

Exclusion criteria

Exclusion Criteria (All Participants):

  • score >6 at Screening.
  • Female participant who is currently pregnant or lactating, or is planning to become pregnant during the study through EOS.
  • Positive test results for HAV IgM, IgM, HBsAg, or 1/2 Ab at Screening.
  • Positive screen for drugs or alcohol (listed in Table 5) at Screening or on Day -2, with the exception of prescription medication (including THC) as determined by the Investigator to be therapeutic.
  • Changes in permitted concomitant medication regimen (defined as starting a new medication[s] or a change in the dosage or frequency of the concomitant medication[s] within 14 days or 5 half-lives [whichever is longer]) before dosing on Day 1.
  • History or presence of a psychiatric or neurological disease within 1 year of Screening.
  • Epilepsy or a history of seizures within the last 2 years (with the exception of febrile seizures).
  • Current evidence or history of suicidal behavior in the past 2 years.
  • History or presence of uncontrolled cardiac diseases including conduction and structural abnormalities, which may place the participant at increased risk as determined by the Investigator.
  • Impairment of GI function or disease that may significantly alter the absorption of ABI-6250 or may predispose the participant to an increased risk of GI toxicity (eg, inflammatory bowel disease, celiac disease, prior gastrectomy, gastric bypass, small bowel resection, etc.).
  • Participant has a portal shunt.
  • Clinically significant history or evidence of pulmonary, neurologic, psychiatric, cardiovascular, hematologic, dermatologic, immunologic, or metabolic disease; or any other condition or organ system disease that in the opinion of the Investigator would jeopardize the safety of the participant or impact validity of study results.
  • Has a , a history of malignancy, or has received treatment for a malignancy at any time, with the exception of resected and cured basal cell carcinoma or squamous cell carcinoma of the skin (>1 year).
  • History or evidence of pancreatic injury or pancreatitis within 6 months of Screening.
  • Ongoing history of any medical condition other than mild hepatic impairment as defined by inclusion criteria #12, #13, #14 #15, and #16 that in the opinion of the Investigator would increase the risk to the participant if enrolled in the study or make the participant unsuitable for the study.
  • Any clinically significant illness in the 30 days before Day -2.
  • Known or allergy to ABI-6250 or constituent of the formulation.
  • Received any drug within 30 days or 5 half-lives of the study drug (whichever is longer) before Screening.
  • Participant has had an immunization within 30 days of Screening. Coronavirus disease 2019 vaccine is allowed if the vaccination took place at least 7 days before Screening.
  • Donation or significant loss of blood or blood products of 500 mL or more within 56 days before Screening, or donation or loss of plasma within 7 days before Screening, or plans to donate blood or plasma through EOS.
  • Participant is unwilling to abstain from consumption of grapefruit, pomelo, or Seville orange whole fruits or juices for 7 days before Day 1 and through EOS.
  • Participant is unwilling to abstain from ingesting caffeine- or xanthine-containing products (eg, coffee, tea, cola drinks, and chocolate) for 24 hours before Admission until discharge from the CRU.
  • Participant is unwilling to abstain from alcohol for 48 hours before Admission until discharge from the CRU.
  • Participant is unwilling or unable to comply with the lifestyle considerations described in this protocol.

Exclusion Criteria for Participants With Mild Hepatic Impairment (Cohort 1):

  • Any finding that, in the judgment of the Investigator, is a clinically significant laboratory abnormality unrelated to the participant's hepatic impairment, including serum chemistry, hematology, coagulation, and urinalysis test results (abnormal test may be repeated for confirmation).
  • Vital sign abnormality after at least 5 minutes resting in the supine position at Screening, Day -2, Day -1, or predose on Day 1.
  • Abnormal standard 12-lead after at least 5 minutes resting in the supine position at Screening, Day -2, or predose on Day 1.
  • Positive test for drugs of abuse, including alcohol at Screening or Admission (Day -2), with the exception of medications under prescription and verified by the Investigator as used for therapeutic management.

Exclusion Criteria for Participants With Normal Hepatic Function (Cohort 2):

  • History or presence of hepatic disease indicated by medical history or abnormal hepatic function.
  • Abnormal vital sign measurements after at least 5 minutes resting in the supine position at Screening, Day -2, Day -1, or predose on Day 1.
  • Abnormal standard 12-lead ECG after at least 5 minutes resting in the supine position at Screening, Day -2, or predose on Day 1.
  • Any finding that, in the judgment of the Investigator, is a clinically significant laboratory abnormality, including serum chemistry, hematology, coagulation, and urinalysis test results (abnormal test results may be repeated for confirmation).
  • Use of any prescription medication or OTC medication, including multivitamins, dietary and herbal supplements within 14 days or 5 half-lives, whichever is longer, before dosing on Day 1 and until the EOS.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cohort 1 & 2, ABI-6250

    Drug: ABI-6250

Interventions

  • Participants will receive ABI-6250 0.5 mg QD over 10 days.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of ABI-6250.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

  2. Apparent Terminal Elimination Half Life (t 1/2) of ABI-6250.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

  3. Time to Cmax (Tmax) of ABI-6250.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

  4. Area Under the Plasma Concentration-Time Curve (AUC) from time zero to 24 hours postdose (AUC0-24) of ABI-6250 on Days 1 and 10.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

  5. Apparent Systemic Clearance (CL/F) of ABI-6250.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

  6. Apparent Volume of Distribution (Vz/F) of ABI-6250.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

  7. Adverse events (AEs).

    Time frame: From enrollment to Day 35.

  8. Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality.

    Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters will be measured: Serum Chemistry: ALT, ALB, Alk phos, AST, BUN, Ca, Co2, Cl, Creatinine kinase, eGFR, GGT, Total Cholesterol, Trig, Glucose, LDH, Potassium, Sodium, T. Bili, D. Bili and I. Bili, Total protein. Hematology: HCT, HGB, MPV, Platelet count, RBC count, RBC indices (MCH, MCHC, MCV, RDW), WBC count, WBC differential (BASO, EOS, LYMPH, MONO, NEUT). Urinalysis: UCLA, UBILQL, UCOL, UGLUQ, UKET, UWEST, UNIT, UOCULT, pH, protein, Specific gravity. Coagulation: aPTT, PT, FIB, INR.

    Time frame: From enrollment to Day 35, at pre-specified timepoints.

  9. Incidence of Clinically Significant Vital Signs Abnormality.

    Number of participants with at least one clinically significant vitals abnormality. The following clinical signs will be measured: systolic blood pressure (mmHg), diastolic blood pressure (mmHg), heart rate (beats/min), respiratory rate (breaths/min), and body temperature (C°).

    Time frame: From enrollment to Day 35, at pre-specified timepoints.

  10. Incidence of Clinically Significant 12-lead Electrocardiogram (ECG) Abnormality.

    Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG will be recorded: PR interval (msec), QRS duration (msec), QT interval (msec), QTCF interval (msec), heart rate (beats/min), RR (msec), and interpretation.

    Time frame: From enrollment to Day 35, at pre-specified timepoints.

  11. Incidence of Clinically Significant Physical Examination Abnormality.

    Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum, assessments of the general appearance, respiratory, cardiovascular, gastrointestinal, musculoskeletal, and dermatological systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement to calculate BMI.

    Time frame: From enrollment to Day 35, at pre-specified timepoints.

Secondary outcomes

  1. Bile acid levels in plasma.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

  2. Coproporphyrin 1 (CP-1) levels in plasma.

    Time frame: From Day 1 to Day 35, at pre-specified timepoints.

Other outcomes

  1. Unbound Cmax (Cmax,u) of ABI-6250.

    Time frame: Day 1 and Day 10, at pre-specified timepoints.

  2. Unbound AUC0-24 (AUC0-24,u) of ABI-6250.

    Time frame: Day 1 and Day 10, at pre-specified timepoints.

  3. Amount of bile acids excreted in urine.

    Time frame: From Day 1 to Day 14, at pre-specified timepoints.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Oct 1, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Clinical laboratory tests.Now Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality.Time frame: From enrollment to Day 35, at pre-specified timepoints.
Oct 16, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 16, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Clinical laboratory tests.Now Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality.Time frame: From enrollment to Day 35, at pre-specified timepoints.
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850999
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Assembly Biosciences
Contact
clinicaltrials@assemblybio.com
833-509-4583

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABI-6250

Start the discussion